Biotech News
Related news
IMTXImmatics2026-10-24 06:30 EST
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
IMTXImmatics2026-11-10 12:00 EST
Immatics Announces Third Quarter 2026 Financial Results and Business Update
ERASErasca2026-11-16 13:01 EST
Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
CGEMCullinan Therapeutics, Inc.2026-11-04 14:14 EST
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
ZNTLZentalis2026-10-23 14:15 EST
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
ZNTLZentalis2026-10-18 22:05 EST
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
BMEABiomea Fusion2026-11-12 21:01 EST
Biomea Fusion to Participate in Upcoming Investor Conferences
NRIXNurix Therapeutics2026-11-10 12:00 EST
Nurix Therapeutics to Participate in Upcoming Investor Conferences
CGEMCullinan Therapeutics, Inc.2026-11-09 15:00 EST
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
MGNXMacroGenics2026-11-05 21:05 EST
MacroGenics to Participate in Upcoming Investor Conferences
Immatics
TCR-Based Solid Tumor Immunotherapy Immatics develops engineered T-cell therapies and TCR bispecifics directed against intracellular cancer targets presented by HLA molecules. PRAME Franchise The company has built multiple modalities around PRAME, a target expressed across more than 50 cancers. Anzu-cel Anzu-cel is an autologous...
Recent company news
IMTXImmatics2026-11-10 12:00 EST
Immatics Announces Third Quarter 2026 Financial Results and Business Update
IMTXImmatics2026-10-24 06:30 EST
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
IMTXImmatics2026-08-25 11:00 EST
Immatics Announces $150 Million Underwritten Offering
IMTXImmatics2026-08-18 11:00 EST
Immatics Announces Second Quarter 2026 Financial Results and Business Update
IMTXImmatics2026-07-17 14:25 EST
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
Stock data
- Close
- 5.95 USD
- Market cap
- 1.37B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
